It is documented that the use of autologous HSP derived from tumours, linked to small tumour proteins and peptides, forming HSP–peptide complexes (HSPPC), can circumvent immune evasion caused by cancer heterogeneity, immunising the host against a broad repertoire of individual tumour-associated antigens (TAA) [23,25]. This evidence concerns the gene HSP90B2P and neoplasm.